The Latest Cardiac and Vascular News
– First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation – New delivery system works with Abbott’s leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and […]
– Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) – Access to MCS devices are critical for advanced heart failure patients and can improve […]
– Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant – The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced it […]
– A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott’s cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure – The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats – Historically, […]
– Sales growth of 35.3 percent; organic sales growth of 32.9 percent – GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent – All four major businesses achieved strong sales growth in the quarter – Projected full-year EPS remains unchanged; reflects growth […]
– New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve – Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient’s complex tricuspid valve anatomy – TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions […]
– New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding – XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that […]
The world’s smallest pediatric treatments, developed by Abbott, meet the needs of the most vulnerable patients: babies and children born with congenital heart defects Approval includes use of a pediatric mechanical heart valve and the first minimally invasive device to treat premature and newborn babies with an opening in the […]
– Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales – Sales growth of 28.7 percent; organic sales growth of 28.4 percent – GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent – Delivered more than 300 million COVID-19 […]
– New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population ABBOTT PARK, Ill., Jan. 20, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) […]
